Skip to main content
Premium Trial:

Request an Annual Quote

Washington Center to Publicly Release Tool That Determines Number of Arrays Needed for Experiments

WASHINGTON, DC, Aug. 25 (GenomeWeb News) - Children's National Medical Center will post an analysis tool within one month that will enable researchers to determine how many microarrays they will need to run a particular experiment, according to an CNMC official.

 

The free tool, called Power Analysis, will be posted on the center's Public Expression Profiling Resource website, an online expression data depository, according to Eric Hoffman, who heads the CNMC's ResearchCenterfor Genetic Medicine. He disclosed the CNMC's plans at Cambridge Healthtech Institute's Total Microarray Data Analysis and Interpretation conference, held here this week.

 

Hoffman said that there was a need for a tool that would allow researchers involved in clinical trials or exploratory research to "design an ethical experiment" using the appropriate number of samples and "alleviate multiple testing problems" by only running as many arrays as were determined to be necessary.

 

Hoffman said the tool had been developed with fellow CNMC scientist Jinwook Seo and others, and that it would be public domain. A paper is in the works.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.